黄金城集团

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway.

Br. J. Pharmacol.. 2018-06; 
BaoLichen,YinJun,GaoWen,WangQun,YaoWenbing,GaoXiang
Products/Services Used Details Operation
… accession no AAQ89444.1), and PsTag600 (NCBI accession no KT964028) were synthesized by GenScript (Nanjing, China). Native FGF21 and PsTag600-FGF21 were purified as … mouse IL17A (Z03031, GenScript, Nanjing, China) twice a day for 15 days. For rIL17A …

摘要

Non-alcoholic steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease and is a serious public health problem around the world. There are currently no approved treatments for NASH. FGF21 has recently emerged as a promising drug candidate for metabolic diseases. However, the disadvantages of FGF21 as a clinically useful medicine include its short plasma half-life and poor drug-like properties. Here, we have explored the effects of PsTag600-FGF21, an engineered long-acting FGF21 fusion protein, in mice with NASH and describe some of the underlying mechanisms.

关键词